The global Intradermal Injection market size was estimated to be US$ 3.3 billion in 2021 and is expected grow at a CAGR of 10.5% between 2023 to 2032.
Intradermal injection is the process by which a drug is injected into the skin. Injection methods may vary from subcutaneous (just beneath the skin's outer surface) to intradermal. Skincare, hormones, vaccines, and medications can all be delivered with an intradermal injection. It has gained popularity among patients because of the efficacy and absorption it delivers, for which a lesser amount is required over time.
The global intradermal injection market has seen significant growth in recent years, especially among emerging markets owing to its easy administration, clinical superiority, and efficacy delivery mechanism (IGST), such as diabetes scales. The metered dose inhaler (MDI), previously used by pharmaceutical firms, is now a less-used treatment form because other mechanisms, such as tablets or syrups, have mainly displaced MDI products. Moreover, new product development, growing awareness about cosmetic surgery, and rising use of injectables will boost the growth. The growing trend of integrative therapies also propels the demand for these products shortly.
Reimbursement policies for these procedures will boost demand and sales in many developed countries due to rising prices leading to stricter emission policies and infections from prescription drugs that can be free of charge before December 2020.
The impacts of competition are witnessed across the Global Intradermal Injection market, where big players compete with price cuts, advertisements, and special offers to make their brands irresistible to consumers. Globally, Augment Therapeutics manufactures high-quality drugs, which pose a significant threat to Intradermal companies in North America and Europe.
Growth driving factors:
Increased Aesthetic Surgical Procedures and an Increasing Prevalence of Chronic Diseases to Promote Intradermal Injection Uptake. The market for intradermal injections is anticipated to rise faster due to TB's increased prevalence. According to WHO statistics, tuberculosis is the 13th most significant cause of death, and there are an estimated 10 million new cases each year. This has caused a dramatic increase in the TB diagnosis rate during the past ten years. This is one of the critical elements contributing significantly to expanding the intradermal injection market for tuberculin syringes.
Additionally, in North America and Europe, cosmetic operations are rising quickly. The intradermal vaccination lowers the possible antigen dosage, enhances the immune response, and lessens vaccination-related anxiety. Additionally, the demand for intradermal injections is rising as aesthetic procedures dominate local aesthetic procedures.
A healthcare setting's resources or refrigerator space are further constrained by the need for cold chain delivery and storage for almost all vaccinations. Each year, animal bites transmit rabies to around 17.4 million humans worldwide. Rabies is a viral illness that affects more than 150 regions and nations, and when it is spread to people, it can result in encephalitis. The price of cell-derived vaccinations for pre-exposure to rabies is significantly reduced via intradermal injections—the cost-savings associated with intradermal injections for rabies present significant market prospects.
Companies in the intradermal injection industry use both organic and inorganic methods. Product releases and product approvals are the major components of organic initiatives. Acquisitions, partnerships, and collaborations are other inorganic growth techniques used in the intradermal injection business. These expansion plans give market participants more geographic reach and commercial opportunities, which helps drive the intradermal injection market's overall expansion.
The intradermal injection market is further divided based on technology into long, short, and no needles. The devices with short needles are further divided into an intradermal liquid jet and ballistic intradermal injectors. In contrast, those without needles are divided into intradermal microinjection, microneedle arrays, and tattoo devices. While the short needle segment is anticipated to experience the highest CAGR between 2023 and 2032, regular-sized needles held most of the market share in 2021.
The market is divided into tuberculin skin testing, allergy testing, regional aesthetics, and other applications based on use. The category for tuberculin skin tests is anticipated to account for the most significant market share in 2021, while the segment for local aesthetics is anticipated to see the highest CAGR throughout the forecast period.
Companies in the intradermal injection industry strongly emphasize implementing a strategy of product development to satisfy customers' changing needs throughout the world, which also enables them to keep their brand identity in the global market.
Intradermal injection-related treatments and equipment have experienced constant innovation over the past several years, and various unique technologies are now included in this category to improve this industry. The adoption of intradermal injections has eventually grown due to the exponential rise in immunization and diagnostic rates for several issues during the past ten years.
Due to the presence of local competitors in the market and the better and simpler availability of intradermal injections in the area, North America is predicted to have the quickest growth in the market during the projection. In North America and Europe, improvements in the healthcare system and government support for intradermal injections are anticipated to expand the market for these procedures significantly. The US commercialization of several intradermal injections.
The FDA has been a significant driver of the global demand for intradermal injections. The intradermal injections market in Asia-Pacific is anticipated to expand significantly throughout the forecast period due to improvements in healthcare spending, rising market participant investment, and rising consumer awareness of the benefits of intradermal injections.
Growth restraining factors:
Unfavorable government policies that impede market expansion. Despite the benefits shown by several clinical studies, several obstacles prevent the use of intradermal injections. The major economies of Europe, the United States, and other industrialized nations depend on single-dose vaccines and have access to public or private insurance. Multi-dose forms are expected to be more prevalent in emerging nations, constrained by supply costs and availability.
The Bristol-Myers Squibb Company, BD, OraSure Technologies Inc., West Pharmaceutical Services Inc., Kyoto Kagaku Co. LTD., Terumo Corporation, and others are some of the major market players active in the global intradermal injections market.
Segmentation of Intradermal Injection Market:
By End Use:
North America will be one of the major geographical markets for intradermal injections.
In the upcoming years, a number of variables are anticipated to impact the intradermal injection market. The market is expanding as a result of factors like rising intradermal vaccination adoption, rising incidence of various communicable and non-communicable diseases, and rising consumer acceptance of aesthetic procedures.
Intradermal injections' risks, side effects, and dosing restrictions, however, are likely to impede market expansion.
The global intradermal injections market is estimated to exhibit a CAGR of 10.5% between 2023 to 2032.
Intradermal injection market size was estimated to be US$ 3.3 billion in 2021.
The short needle segment is anticipated to experience the highest CAGR between 2023 and 2032.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved